The Oestrogenic Effects of Ethinyl Oestradiol/Polyoestradiol Phosphate and Estramustine Phosphate in Patients with Prostatic Carcinoma A Comparative Study of Oestrogen Sensitive Liver Proteins, Gonadotrophins and Prolactin

Abstract

Thirty previously untreated patients with carcinoma of the prostate were prospectively randomised to one of the following treatments: ethinyl oestradiol (Etivex) combined with polyoestradiol phosphate (Estradurin); estramustine phosphate (Estracyt); bilateral orchiectomy. Oestrogenic effects were measured by blood levels of pregnancy zone protein, sex hormone binding globulin, LH, FSH and prolactin. During a follow-up period of 6 months, estramustine phosphate and ethinyl oestradiol/polyoestradiol phosphate induced comparable changes in these proteins, suggesting comparable oestrogenic effects of these two forms of treatment in patients with prostatic carcinoma.